Our laboratory's major focus is on the development of novel methods to treat brain injury, particularly the type of brain injury that leads to epilepsy. We work to identify biological targets which can stop or prevent seizures if manipulated by either brain stimulation or by novel drugs that we are testing in our lab.

We have adapted methods for transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) to rodents, to in vitro brain slice preparations, and more recently to zebrafish (an emerging experimental tool in epilepsy). TMS and tDCS have in common the capacity to safely induce durable changes in neuronal activity. Limited experience with human patients, including those treated at Boston Children's Hospital, shows that TMS and tDCS have realistic prospects in suppressing seizures. Yet whether these techniques can prevent the onset of epilepsy after various forms of brain injury has not been tested. To characterize the cellular mechanisms by which TMS and tDCS exert their effect, and ultimately to optimize their clinical efficacy, we are testing these techniques in rodent epilepsy models, including models of traumatic brain injury (TBI).

To determine how best to match the cellular changes induced by noninvasive brain stimulation those of brain injury and epilepsy, we are also studying the molecular changes associated with TBI in rats. A second major focus has grown out of this work: testing novel pharmaceutical approaches to prevent brain injury and seizures after TBI.

In parallel to our laboratory experiments, we have ongoing clinical projects aimed to further develop techniques for noninvasive brain stimulation, particularly TMS and tDCS, as diagnostic and therapeutic tools in child neurology.



Alex Rotenberg was born in Chernovtsy, Ukraine. He is a graduate of Johns Hopkins University (BA) and the State University of New York, Downstate Medical Center (MD, PhD). He is an active member of the American Epilepsy Society. His current appointment is as Associate Professor of Neurology, Harvard Medical School. Dr. Rotenberg is the recipient of the 2016 Dreifuss-Penry Epilepsy Award from the American Academy of Neurology.


Publications powered by Harvard Catalyst Profiles

  1. A "Proof of Concept" Randomized Controlled Trial of a Video Game Requiring Emotional Regulation to Augment Anger Control Training. Front Psychiatry. 2021; 12:591906. View abstract
  2. Clinical Characterization of Epilepsy in Children With Angelman Syndrome. Pediatr Neurol. 2021 Nov; 124:42-50. View abstract
  3. Personalised, image-guided, noninvasive brain stimulation in gliomas: Rationale, challenges and opportunities. EBioMedicine. 2021 Aug; 70:103514. View abstract
  4. Biomarkers Obtained by Transcranial Magnetic Stimulation in Neurodevelopmental Disorders. J Clin Neurophysiol. 2021 Aug 03. View abstract
  5. Factors influencing the acute pentylenetetrazole-induced seizure paradigm and a literature review. Ann Clin Transl Neurol. 2021 07; 8(7):1388-1397. View abstract
  6. Cis P-tau underlies vascular contribution to cognitive impairment and dementia and can be effectively targeted by immunotherapy in mice. Sci Transl Med. 2021 06 02; 13(596). View abstract
  7. Transcranial Magnetic Stimulation in Succinic Semialdehyde Dehydrogenase Deficiency: A Measure of Maturational Trajectory of Cortical Excitability. J Child Neurol. 2021 May 31; 8830738211008735. View abstract
  8. Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation. Transl Psychiatry. 2021 05 27; 11(1):325. View abstract
  9. Personalized, Multisession, Multichannel Transcranial Direct Current Stimulation in Medication-Refractory Focal Epilepsy: An Open-Label Study. J Clin Neurophysiol. 2021 May 14. View abstract
  10. Modulation of motor cortical excitability by continuous theta-burst stimulation in adults with autism spectrum disorder. Clin Neurophysiol. 2021 07; 132(7):1647-1662. View abstract
  11. Enzyme Replacement Therapy for Succinic Semialdehyde Dehydrogenase Deficiency: Relevance in ?-Aminobutyric Acid Plasticity. J Child Neurol. 2021 Feb 24; 883073821993000. View abstract
  12. A pathogenic UFSP2 variant in an autosomal recessive form of pediatric neurodevelopmental anomalies and epilepsy. Genet Med. 2021 05; 23(5):900-908. View abstract
  13. In-session seizures during transcranial direct current stimulation in patients with epilepsy. Brain Stimul. 2021 Jan-Feb; 14(1):152-153. View abstract
  14. EEG markers predictive of epilepsy risk in pediatric cerebral malaria - A feasibility study. Epilepsy Behav. 2020 12; 113:107536. View abstract
  15. Increase in Seizure Susceptibility After Repetitive Concussion Results from Oxidative Stress, Parvalbumin-Positive Interneuron Dysfunction and Biphasic Increases in Glutamate/GABA Ratio. Cereb Cortex. 2020 11 03; 30(12):6108-6120. View abstract
  16. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 01; 132(1):269-306. View abstract
  17. Drug-Responsive Inhomogeneous Cortical Modulation by Direct Current Stimulation. Ann Neurol. 2020 09; 88(3):489-502. View abstract
  18. Review of Transcranial Magnetic Stimulation in Epilepsy. Clin Ther. 2020 07; 42(7):1155-1168. View abstract
  19. Targeting Gamma-Related Pathophysiology in Autism Spectrum Disorder Using Transcranial Electrical Stimulation: Opportunities and Challenges. Autism Res. 2020 07; 13(7):1051-1071. View abstract
  20. Localized Disruption of Blood Albumin-Phenytoin Binding Using Transcranial Focused Ultrasound. Ultrasound Med Biol. 2020 08; 46(8):1986-1997. View abstract
  21. Continuous Theta-Burst Stimulation in Children With High-Functioning Autism Spectrum Disorder and Typically Developing Children. Front Integr Neurosci. 2020; 14:13. View abstract
  22. Noninvasive Brain Stimulation in Epilepsy. J Clin Neurophysiol. 2020 Mar; 37(2):118-130. View abstract
  23. Safety and Tolerability of Repetitive Transcranial Magnetic Stimulation During Pregnancy: A Case Report and Literature Review. J Clin Neurophysiol. 2020 Mar; 37(2):164-169. View abstract
  24. Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? Epilepsia. 2020 03; 61(3):359-386. View abstract
  25. Emerging Applications of Noninvasive Brain Stimulation. J Clin Neurophysiol. 2020 03; 37(2):89. View abstract
  26. Cortical Excitability, Synaptic Plasticity, and Cognition in Benign Epilepsy With Centrotemporal Spikes: A Pilot TMS-EMG-EEG Study. J Clin Neurophysiol. 2020 Mar; 37(2):170-180. View abstract
  27. Transcranial magnetic stimulation tracks subminute changes in cortical excitability during propofol anesthesia. Ann Clin Transl Neurol. 2020 03; 7(3):384-389. View abstract
  28. Early transcranial direct current stimulation treatment exerts neuroprotective effects on 6-OHDA-induced Parkinsonism in rats. Brain Stimul. 2020 May - Jun; 13(3):655-663. View abstract
  29. Patterns of anti-seizure medication (ASM) use in pediatric patients with surgically managed epilepsy: A retrospective review of data from Boston Children's Hospital. Epilepsy Res. 2020 02; 160:106257. View abstract
  30. Safety of rTMS in patients with intracranial metallic objects. Brain Stimul. 2020 May - Jun; 13(3):928-929. View abstract
  31. Ceftriaxone Treatment Preserves Cortical Inhibitory Interneuron Function via Transient Salvage of GLT-1 in a Rat Traumatic Brain Injury Model. Cereb Cortex. 2019 12 17; 29(11):4506-4518. View abstract
  32. Neuromodulatory Effects of Transcranial Direct Current Stimulation on Motor Excitability in Rats. Neural Plast. 2019; 2019:4252943. View abstract
  33. Biomarkers Obtained by Transcranial Magnetic Stimulation of the Motor Cortex in Epilepsy. Front Integr Neurosci. 2019; 13:57. View abstract
  34. Regulation of lifespan by neural excitation and REST. Nature. 2019 10; 574(7778):359-364. View abstract
  35. Maturation of Corticospinal Tracts in Children With Hemiplegic Cerebral Palsy Assessed by Diffusion Tensor Imaging and Transcranial Magnetic Stimulation. Front Hum Neurosci. 2019; 13:254. View abstract
  36. Test-Retest Reliability of the Effects of Continuous Theta-Burst Stimulation. Front Neurosci. 2019; 13:447. View abstract
  37. Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism. Ann Neurol. 2019 06; 85(6):921-926. View abstract
  38. De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and Dyskinesias. Am J Hum Genet. 2019 Mar 07; 104(3):562. View abstract
  39. Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes. Biol Psychiatry. 2019 05 01; 85(9):752-759. View abstract
  40. Electrographic spikes are common in wildtype mice. Epilepsy Behav. 2018 12; 89:94-98. View abstract
  41. De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and Dyskinesias. Am J Hum Genet. 2018 11 01; 103(5):666-678. View abstract
  42. Dietary, immunological, surgical, and other emerging treatments for pediatric refractory status epilepticus. Seizure. 2019 May; 68:89-96. View abstract
  43. Succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism: an update on pharmacological and enzyme-replacement therapeutic strategies. J Inherit Metab Dis. 2018 07; 41(4):699-708. View abstract
  44. A mouse model of DEPDC5-related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility. Neurobiol Dis. 2018 03; 111:91-101. View abstract
  45. The Need for Antiepileptic Drug Chronotherapy to Treat Selected Childhood Epilepsy Syndromes and Avert the Harmful Consequences of Drug Resistance. J Cent Nerv Syst Dis. 2017; 9:1179573516685883. View abstract
  46. mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex. Neuropsychopharmacology. 2018 05; 43(6):1457-1465. View abstract
  47. Trajectory of Parvalbumin Cell Impairment and Loss of Cortical Inhibition in Traumatic Brain Injury. Cereb Cortex. 2017 12 01; 27(12):5509-5524. View abstract
  48. Alterations in the Timing of Huperzine A Cerebral Pharmacodynamics in the Acute Traumatic Brain Injury Setting. J Neurotrauma. 2018 01 15; 35(2):393-397. View abstract
  49. A randomized controlled trial of levodopa in patients with Angelman syndrome. Am J Med Genet A. 2018 05; 176(5):1099-1107. View abstract
  50. Interindividual variability in response to continuous theta-burst stimulation in healthy adults. Clin Neurophysiol. 2017 11; 128(11):2268-2278. View abstract
  51. Persistent uncrossed corticospinal connections in patients with intractable focal epilepsy. Epilepsy Behav. 2017 10; 75:66-71. View abstract
  52. Correction: Relationship of mechanical impact magnitude to neurologic dysfunction severity in a rat traumatic brain injury model. PLoS One. 2017; 12(7):e0182300. View abstract
  53. Response to letter to the editor: Safety of transcranial direct current stimulation: Evidence based update 2016. Brain Stimul. 2017 Sep - Oct; 10(5):986-987. View abstract
  54. Replicable in vivo physiological and behavioral phenotypes of the Shank3B null mutant mouse model of autism. Mol Autism. 2017; 8:26. View abstract
  55. Relationship of mechanical impact magnitude to neurologic dysfunction severity in a rat traumatic brain injury model. PLoS One. 2017; 12(5):e0178186. View abstract
  56. Memantine improves outcomes after repetitive traumatic brain injury. Behav Brain Res. 2018 03 15; 340:195-204. View abstract
  57. Surface EEG-Transcranial Direct Current Stimulation (tDCS) Closed-Loop System. Int J Neural Syst. 2017 Sep; 27(6):1750026. View abstract
  58. The Number of Pulses Needed to Measure Corticospinal Excitability by Navigated Transcranial Magnetic Stimulation: Eyes Open vs. Close Condition. Front Hum Neurosci. 2017; 11:121. View abstract
  59. Transcranial Magnetic and Direct Current Stimulation in Children. Curr Neurol Neurosci Rep. 2017 02; 17(2):11. View abstract
  60. Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease. Med Hypotheses. 2017 Feb; 99:57-62. View abstract
  61. Neurophysiological evidence of preserved connectivity in tuber tissue. Epilepsy Behav Case Rep. 2017; 7:64-68. View abstract
  62. Characterizing and Modulating Brain Circuitry through Transcranial Magnetic Stimulation Combined with Electroencephalography. Front Neural Circuits. 2016; 10:73. View abstract
  63. Pediatric Neuromodulation Comes of Age. J Child Adolesc Psychopharmacol. 2016 09; 26(7):578-81. View abstract
  64. Bursts of high-frequency repetitive transcranial magnetic stimulation (rTMS), together with lorazepam, suppress seizures in a rat kainate status epilepticus model. Epilepsy Behav. 2016 09; 62:136-9. View abstract
  65. Correction: Microarray Noninvasive Neuronal Seizure Recordings from Intact Larval Zebrafish. PLoS One. 2016; 11(7):e0159472. View abstract
  66. Direct current stimulation induces mGluR5-dependent neocortical plasticity. Ann Neurol. 2016 08; 80(2):233-46. View abstract
  67. Construction and Evaluation of Rodent-Specific rTMS Coils. Front Neural Circuits. 2016; 10:47. View abstract
  68. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct; 9(5):641-661. View abstract
  69. Microarray Noninvasive Neuronal Seizure Recordings from Intact Larval Zebrafish. PLoS One. 2016; 11(6):e0156498. View abstract
  70. Abnormal Mechanisms of Plasticity and Metaplasticity in Autism Spectrum Disorders and Fragile X Syndrome. J Child Adolesc Psychopharmacol. 2016 09; 26(7):617-24. View abstract
  71. Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research. Expert Rev Neurother. 2016 06; 16(6):671-80. View abstract
  72. H-coil repetitive transcranial magnetic stimulation for treatment of temporal lobe epilepsy: A case report. Epilepsy Behav Case Rep. 2016; 5:52-6. View abstract
  73. Safety of repetitive transcranial magnetic stimulation in patients with epilepsy: A systematic review. Epilepsy Behav. 2016 Apr; 57(Pt A):167-176. View abstract
  74. N100 Repetition Suppression Indexes Neuroplastic Defects in Clinical High Risk and Psychotic Youth. Neural Plast. 2016; 2016:4209831. View abstract
  75. Noninvasive Brain Stimulation in Pediatric Attention-Deficit Hyperactivity Disorder (ADHD): A Review. J Child Neurol. 2016 May; 31(6):784-96. View abstract
  76. Early auditory processing evoked potentials (N100) show a continuum of blunting from clinical high risk to psychosis in a pediatric sample. Schizophr Res. 2015 Dec; 169(1-3):340-345. View abstract
  77. Transcranial magnetic stimulation in autism spectrum disorder: Challenges, promise, and roadmap for future research. Autism Res. 2016 Feb; 9(2):184-203. View abstract
  78. Neurophysiological differences between patients clinically at high risk for schizophrenia and neurotypical controls--first steps in development of a biomarker. BMC Med. 2015 Nov 02; 13:276. View abstract
  79. Huperzine A prophylaxis against pentylenetetrazole-induced seizures in rats is associated with increased cortical inhibition. Epilepsy Res. 2015 Nov; 117:97-103. View abstract
  80. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015 Jul 23; 523(7561):431-436. View abstract
  81. Acute seizure suppression by transcranial direct current stimulation in rats. Ann Clin Transl Neurol. 2015 Aug; 2(8):843-56. View abstract
  82. Commentary on IL-1ß associations with posttraumatic epilepsy development: A genetics and biomarker cohort study. Epilepsia. 2015 Jul; 56(7):989-90. View abstract
  83. Glutamate and GABA imbalance following traumatic brain injury. Curr Neurol Neurosci Rep. 2015 May; 15(5):27. View abstract
  84. Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression. Proc Natl Acad Sci U S A. 2015 Apr 21; 112(16):5129-34. View abstract
  85. Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes. J Neurosci. 2015 Apr 01; 35(13):5187-201. View abstract
  86. Use of transcranial magnetic stimulation in autism spectrum disorders. J Autism Dev Disord. 2015 Feb; 45(2):524-36. View abstract
  87. Transcranial magnetic stimulation (TMS) therapy for autism: an international consensus conference held in conjunction with the international meeting for autism research on May 13th and 14th, 2014. Front Hum Neurosci. 2014; 8:1034. View abstract
  88. 15years of welcome contribution to epilepsy research. Epilepsy Behav. 2014 Nov; 40:127. View abstract
  89. Passive fMRI mapping of language function for pediatric epilepsy surgical planning: validation using Wada, ECS, and FMAER. Epilepsy Res. 2014 Dec; 108(10):1874-88. View abstract
  90. Hippocampal immediate early gene transcription in the rat fluid percussion traumatic brain injury model. Neuroreport. 2014 Aug 20; 25(12):954-9. View abstract
  91. Modulation of corticospinal excitability by transcranial magnetic stimulation in children and adolescents with autism spectrum disorder. Front Hum Neurosci. 2014; 8:627. View abstract
  92. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia. 2014 Aug; 55(8):1235-44. View abstract
  93. EEG abnormalities and seizures in genetically diagnosed Fragile X syndrome. Int J Dev Neurosci. 2014 Nov; 38:155-60. View abstract
  94. Comparison of pediatric patients with status epilepticus lasting 5-29 min versus =30 min. Epilepsy Behav. 2014 Aug; 37:1-6. View abstract
  95. Comparison of risk factors for pediatric convulsive status epilepticus when defined as seizures = 5 min versus seizures = 30 min. Seizure. 2014 Oct; 23(9):692-8. View abstract
  96. Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior. BMC Neurol. 2014 May 15; 14:70. View abstract
  97. A rapid lateral fluid percussion injury rodent model of traumatic brain injury and post-traumatic epilepsy. Neuroreport. 2014 May 07; 25(7):532-6. View abstract
  98. Suppression of motor cortical excitability in anesthetized rats by low frequency repetitive transcranial magnetic stimulation. PLoS One. 2014; 9(3):e91065. View abstract
  99. Rasmussen's encephalitis presenting as focal cortical dysplasia. Epilepsy Behav Case Rep. 2014; 2:86-9. View abstract
  100. A measure of acoustic noise generated from transcranial magnetic stimulation coils. Brain Stimul. 2014 May-Jun; 7(3):432-4. View abstract
  101. Functional Dopaminergic Neurons in Substantia Nigra are Required for Transcranial Magnetic Stimulation-Induced Motor Plasticity. Cereb Cortex. 2015 Jul; 25(7):1806-14. View abstract
  102. Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. Pediatr Neurol. 2014 Jul; 51(1):60-6. View abstract
  103. Outcomes of vagal nerve stimulation in a pediatric population: a single center experience. Seizure. 2014 Feb; 23(2):105-11. View abstract
  104. Long-term response to high-dose diazepam treatment in continuous spikes and waves during sleep. Pediatr Neurol. 2013 Sep; 49(3):163-170.e4. View abstract
  105. Continuous Spikes and Waves during Sleep: Electroclinical Presentation and Suggestions for Management. Epilepsy Res Treat. 2013; 2013:583531. View abstract
  106. Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat. J Neurotrauma. 2013 Aug 15; 30(16):1434-41. View abstract
  107. Transcranial magnetic stimulation for refractory focal status epilepticus in the intensive care unit. Seizure. 2013 Dec; 22(10):893-6. View abstract
  108. Electroencephalography in the pediatric emergency department: when is it most useful? J Child Neurol. 2014 Apr; 29(4):475-82. View abstract
  109. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS One. 2013; 8(3):e57148. View abstract
  110. Transcranial direct current stimulation for treatment of refractory childhood focal epilepsy. Brain Stimul. 2013 Jul; 6(4):696-700. View abstract
  111. "RAGE-Control": A Game to Build Emotional Strength. Games Health J. 2013 Feb; 2(1):53-7. View abstract
  112. The frequency modulated auditory evoked response (FMAER), a technical advance for study of childhood language disorders: cortical source localization and selected case studies. BMC Neurol. 2013 Jan 25; 13:12. View abstract
  113. Automated quantification of spikes. Epilepsy Behav. 2013 Feb; 26(2):143-52. View abstract
  114. Epilepsy. Handb Clin Neurol. 2013; 116:491-7. View abstract
  115. Migraine prophylaxis by anodal transcranial direct current stimulation, a randomized, placebo-controlled trial. J Med Assoc Thai. 2012 Aug; 95(8):1003-12. View abstract
  116. Translational neuromodulation: approximating human transcranial magnetic stimulation protocols in rats. Neuromodulation. 2012 Jul; 15(4):296-305. View abstract
  117. Circadian patterns of generalized tonic-clonic evolutions in pediatric epilepsy patients. Seizure. 2012 Sep; 21(7):535-9. View abstract
  118. Clinical staging and electroencephalographic evolution of continuous spikes and waves during sleep. Epilepsia. 2012 Jul; 53(7):1185-95. View abstract
  119. Short-term response of sleep-potentiated spiking to high-dose diazepam in electric status epilepticus during sleep. Pediatr Neurol. 2012 May; 46(5):312-8. View abstract
  120. Early thalamic lesions in patients with sleep-potentiated epileptiform activity. Neurology. 2012 May 29; 78(22):1721-7. View abstract
  121. Patients with electrical status epilepticus in sleep share similar clinical features regardless of their focal or generalized sleep potentiation of epileptiform activity. J Child Neurol. 2013 Jan; 28(1):83-9. View abstract
  122. Reply to letter to the editor. Brain Stimul. 2013 Jan; 6(1):95. View abstract
  123. Contribution of axonal orientation to pathway-dependent modulation of excitatory transmission by direct current stimulation in isolated rat hippocampus. J Neurophysiol. 2012 Apr; 107(7):1881-9. View abstract
  124. Transcranial magnetic stimulation induces current pulses in transcranial direct current stimulation electrodes. Annu Int Conf IEEE Eng Med Biol Soc. 2012; 2012:811-4. View abstract
  125. Minimal heating of aneurysm clips during repetitive transcranial magnetic stimulation. Clin Neurophysiol. 2012 Jul; 123(7):1471-3. View abstract
  126. A new measure of cortical inhibition by mechanomyography and paired-pulse transcranial magnetic stimulation in unanesthetized rats. J Neurophysiol. 2012 Feb; 107(3):966-72. View abstract
  127. [The use of noninvasive brain stimulation in childhood psychiatric disorders: new diagnostic and therapeutic opportunities and challenges]. Rev Neurol. 2011 Aug 16; 53(4):209-25. View abstract
  128. Characterizing brain cortical plasticity and network dynamics across the age-span in health and disease with TMS-EEG and TMS-fMRI. Brain Topogr. 2011 Oct; 24(3-4):302-15. View abstract
  129. Safety and tolerability of repetitive transcranial magnetic stimulation in patients with pathologic positive sensory phenomena: a review of literature. Brain Stimul. 2012 Jul; 5(3):320-329.e27. View abstract
  130. Commentary on Kratz et Al "seizure in a nonpredisposed individual induced by single-pulse transcranial magnetic stimulation". J ECT. 2011 Jun; 27(2):176-7. View abstract
  131. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol. 2011 Jun; 44(6):414-9. View abstract
  132. Teaching Video NeuroImages: complex partial seizure evolving into a psychogenic nonepileptic seizure. Neurology. 2011 May 10; 76(19):1681; author reply 1681. View abstract
  133. Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimul. 2012 Jul; 5(3):175-195. View abstract
  134. Transcranial brain stimulation: clinical applications and future directions. Neurosurg Clin N Am. 2011 Apr; 22(2):233-51, ix. View abstract
  135. Development of later life spontaneous seizures in a rodent model of hypoxia-induced neonatal seizures. Epilepsia. 2011 Apr; 52(4):753-65. View abstract
  136. Rufinamide for the treatment of epileptic spasms. Epilepsy Behav. 2011 Feb; 20(2):344-8. View abstract
  137. An estimate of placebo effect of repetitive transcranial magnetic stimulation in epilepsy. Epilepsy Behav. 2011 Feb; 20(2):355-9. View abstract
  138. Measures of cortical inhibition by paired-pulse transcranial magnetic stimulation in anesthetized rats. J Neurophysiol. 2011 Feb; 105(2):615-24. View abstract
  139. Teaching Video NeuroImages: complex partial seizure evolving into a psychogenic nonepileptic seizure. Neurology. 2010 Dec 14; 75(24):e98. View abstract
  140. Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neurol. 2010 Sep; 43(3):155-8. View abstract
  141. Transcranial magnetic stimulation provides means to assess cortical plasticity and excitability in humans with fragile x syndrome and autism spectrum disorder. Front Synaptic Neurosci. 2010; 2:26. View abstract
  142. Trisomy 8 mosaicism and favorable outcome after treatment of infantile spasms: case report. J Child Neurol. 2010 Oct; 25(10):1275-7. View abstract
  143. High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. Epilepsia. 2010 Jul; 51(7):1319-22. View abstract
  144. Prospects for clinical applications of transcranial magnetic stimulation and real-time EEG in epilepsy. Brain Topogr. 2010 Jan; 22(4):257-66. View abstract
  145. Lateralization of forelimb motor evoked potentials by transcranial magnetic stimulation in rats. Clin Neurophysiol. 2010 Jan; 121(1):104-8. View abstract
  146. In-session seizures during low-frequency repetitive transcranial magnetic stimulation in patients with epilepsy. Epilepsy Behav. 2009 Oct; 16(2):353-5. View abstract
  147. Safety of 1 Hz repetitive transcranial magnetic stimulation (rTMS) in patients with titanium skull plates. Clin Neurophysiol. 2009 Jul; 120(7):1417. View abstract
  148. Seizure suppression by EEG-guided repetitive transcranial magnetic stimulation in the rat. Clin Neurophysiol. 2008 Dec; 119(12):2697-702. View abstract
  149. Repetitive transcranial magnetic stimulation in the treatment of epilepsia partialis continua. Epilepsy Behav. 2009 Jan; 14(1):253-7. View abstract
  150. Transient suppression of seizures by repetitive transcranial magnetic stimulation in a case of Rasmussen's encephalitis. Epilepsy Behav. 2008 Jul; 13(1):260-2. View abstract
  151. Transcranial magnetic stimulation in child neurology: current and future directions. J Child Neurol. 2008 Jan; 23(1):79-96. View abstract
  152. Minimal heating of titanium skull plates during 1Hz repetitive transcranial magnetic stimulation. Clin Neurophysiol. 2007 Nov; 118(11):2536-8. View abstract
  153. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci. 2007 May 23; 27(21):5546-58. View abstract
  154. Safety and tolerability of repetitive transcranial magnetic stimulation in patients with epilepsy: a review of the literature. Epilepsy Behav. 2007 Jun; 10(4):521-8. View abstract
  155. Electroencephalographic recording during transcranial magnetic stimulation in humans and animals. Clin Neurophysiol. 2006 Aug; 117(8):1870-5. View abstract
  156. Seizure-induced changes in place cell physiology: relationship to spatial memory. J Neurosci. 2003 Dec 17; 23(37):11505-15. View abstract
  157. Parallel instabilities of long-term potentiation, place cells, and learning caused by decreased protein kinase A activity. J Neurosci. 2000 Nov 01; 20(21):8096-102. View abstract
  158. Variable place-cell coupling to a continuously viewed stimulus: evidence that the hippocampus acts as a perceptual system. Philos Trans R Soc Lond B Biol Sci. 1997 Oct 29; 352(1360):1505-13. View abstract
  159. Mice expressing activated CaMKII lack low frequency LTP and do not form stable place cells in the CA1 region of the hippocampus. Cell. 1996 Dec 27; 87(7):1351-61. View abstract